CORRECTION Qlife Q4 2023
Earlier press release did not include the CEO statement and should have been marked with the MAR legend as it contains insider information.Financial summary – fourth quarter 2023 · Revenue in the period amounted to kSEK 30 (1,097). Revenue includes sales of Egoo.Health devices and capsules for the device. Revenue in Q4 is solely from test orders of CRP capsules and Egoo systems. · EBITDA for the period amounted to kSEK –9,466 (-16,843), and net loss kSEK –111,547 (-25,413). · The total cash flow in the fourth quarter amounted to kSEK -6,095 (3,103). · Earnings per share before/